Phaseline

Targets › CCR8

CCR8 (C-C chemokine receptor type 8): drug programs, companies and trials

5 programs from 5 companies in 7 trials: 4 Phase 1, 2 Phase 2, 1 Phase 3; Oncology; next expected readout Apr 2027.

G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18. Regulates monocyte and eosinophil chemotaxis. (UniProt, P51685)

Open in Phaseline: the race on CCR8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
LaNova MedicinesLM-108
Anti-CCR8 monoclonal antibody
CCR8Phase 3Locally Advanced or Metastatic GC and GCJ Adenocarcinoma; Advanced Solid TumorAug 2028
Bristol-Myers SquibbImzokitug
Anti-CCR8 monoclonal antibody
CCR8Phase 2Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Pancreatic AdenocarcinomaSep 2028
BayerBAY3375968 (Lanerkitug)
Anti-CCR8 antibody
CCR8Phase 1Advanced Solid TumorsApr 2027
Domain Therapeutics AustraliaDT-7012
anti-CCR8 monoclonal antibody
CCR8Phase 1Advanced Solid TumorsSep 2027
TakedaTAK-188
CCR8 antagonist targeting regulatory T cells (Tregs)
CCR8Phase 1Advanced or Metastatic Solid TumorsDec 2028

Conditions

Advanced Solid Tumors (2) Advanced or Metastatic Solid Tumors (1) Locally Advanced or Metastatic GC and GCJ Adenocarcinoma (1) Advanced Solid Tumor (1) Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (1) Metastatic Pancreatic Adenocarcinoma (1)

Modalities

small molecule (2), mixed (2), antibody (1)

Companies

Takeda (1) LaNova Medicines (1) Domain Therapeutics Australia (1) Bristol-Myers Squibb (1) Bayer (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.